Table III.
Clinicopathological features and details of genetic mutations in non-PDAC patients.
| Sample ID | Final diagnosis | Age | Gender | Histology | KRAS mutation (NGS) | Amino acid substitution (TaqMan) | TP53 mutation (NGS) | Other mutations |
|---|---|---|---|---|---|---|---|---|
| 28 | Metastatic pancreatic cancer | 45 | F | No malignancy | − | − | + | |
| 29 | Metastatic pancreatic cancer | 86 | F | Adenocarcinoma | − | − | − | BRAF, VHL, GNAS |
| 30 | NET | 55 | M | NET | − | − | − | |
| 31 | NET | 46 | M | No malignancy | − | − | − | |
| 32 | IPMN | 64 | F | No malignancy | − | − | − | |
| 33 | SCN | 68 | M | No malignancy | − | − | − | |
| 34 | AIP | 77 | M | No malignancy | − | − | − | |
| 35 | AIP | 71 | F | No malignancy | − | G12D | − | |
| 36 | AIP | 67 | M | No malignancy | − | − | − | |
| 37 | CP | 52 | M | No malignancy | − | − | − | |
| 38 | CP | 47 | M | No malignancy | − | − | − |
M, male; F, female; AIP, autoimmune pancreatitis; CP, chronic pancreatitis; EUS-FNA, endoscopic ultrasound-guided fine-needle aspiration; IPMN, intraductal papillary mucinous neoplasm; NET, neuroendocrine tumors; NGS, next generation sequencing; PDAC, pancreatic ductal adenocarcinoma; SCN, serous cystic neoplasm; TP53, tumor protein 53; BRAF, proto-oncogene B-RAF; VHL, von Hippel-Lindau tumor suppressor; GNAS, GNAS complex locus.